TARS
NASDAQ · Pharmaceuticals
Tarsus Pharmaceuticals Inc
$61.21
-2.75 (-4.30%)
Financial Highlights (FY 2026)
Revenue
480.37M
Net Income
-70,688,696
Gross Margin
93.2%
Profit Margin
-14.7%
Rev Growth
+159.5%
D/E Ratio
0.21
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.2% | 93.0% | 38.7% | 38.7% |
| Operating Margin | -15.7% | -60.3% | 24.6% | 25.5% |
| Profit Margin | -14.7% | -60.0% | 21.1% | 26.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 480.37M | 141.37M | 563.29M | 601.92M |
| Gross Profit | 447.70M | 131.46M | 218.10M | 233.06M |
| Operating Income | -75,513,895 | -85,196,544 | 138.76M | 153.21M |
| Net Income | -70,688,696 | -80,362,652 | 118.73M | 157.82M |
| Gross Margin | 93.2% | 93.0% | 38.7% | 38.7% |
| Operating Margin | -15.7% | -60.3% | 24.6% | 25.5% |
| Profit Margin | -14.7% | -60.0% | 21.1% | 26.2% |
| Rev Growth | +159.5% | +47.5% | +0.6% | +19.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 237.04M | 337.23M | 907.11M | 1.12B |
| Total Equity | 1.12B | 1.05B | 2.03B | 1.84B |
| D/E Ratio | 0.21 | 0.32 | 0.45 | 0.61 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -74,833,252 | -89,061,843 | 174.10M | 181.32M |
| Free Cash Flow | — | — | 127.20M | 157.68M |